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Abstract
Background: Robust diagnosis of dementia requires an understanding of the accuracy of the available diagnostic
tests. Informant questionnaires are frequently used to assess for dementia in clinical practice. Recent systematic
reviews have sought to establish the diagnostic test accuracy of various dementia informant screening tools.
However, most reviews to date have focused on a single diagnostic tool and this does not address which tool is
‘best’. A key aim of the overview of systematic reviews is to present a disparate evidence base in a single, easy to
access platform.
Methods: We will conduct an overview of systematic reviews in which we ‘review the systematic reviews’ of
diagnostic test accuracy studies evaluating informant questionnaires for dementia. As an overview of systematic
reviews of test accuracy is a relatively novel approach, we will use this review to explore methods for visual
representation of complex data, for highlighting evidence gaps and for indirect comparative analyses. We will
create a list of informant tools by consulting with dementia experts. We will search 6 databases (EMBASE (OVID);
Health and Psychosocial Instruments (OVID); Medline (OVID); CINAHL (EBSCO); PSYCHinfo (EBSCO) and the
PROSPERO registry of review protocols) to identify systematic reviews that describe the diagnostic test accuracy of
informant questionnaires for dementia. We will assess review quality using the AMSTAR-2 (Assessment of Multiple
Systematic Reviews) and assess reporting quality using PRISMA-DTA (Preferred Reporting Items for Systematic
Review and Meta-analysis of Diagnostic Test Accuracy Studies) checklists. We will collate the identified reviews to
create an ‘evidence map’ that highlights where evidence does and does not exist in relation to informant
questionnaires. We will pool sensitivity and specificity data via meta-analysis to generate a diagnostic test accuracy
summary statistic for each informant questionnaire. If data allow, we will perform a statistical comparison of the
diagnostic test accuracy of each informant questionnaire using a network approach.
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Discussion: Our overview of systematic reviews will provide a concise summary of the diagnostic test accuracy of
informant tools and highlight areas where evidence is currently lacking in this regard. It will also apply network
meta-analysis techniques to a new area.
Keywords: Dementia, Cognitive impairment, Diagnostic accuracy, Informant, Screening, Systematic review, Protocol,
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Background
Dementia is a prevalent and ever-increasing public
health issue [1–3]. Depending upon the case definition
applied, global prevalence of dementia is estimated to be
50 million [4].
The key to the effective management of dementia is
early diagnosis. The ideal method for diagnosing demen-
tia involves comprehensive multidisciplinary assessment
informed by supplementary information such as neuro-
psychological testing, neuroimaging or tissue biomarkers
[5]. However, this time-consuming approach requires
specialist hospital-based services that are a limited re-
source in high-income countries. Thus, the ‘ideal’ ap-
proach to assessment is only feasible for a small
proportion of the potential population affected.
In practice, a two-stage process is typically employed,
with an initial screening process—often carried out by
non-specialists—that is used to identify those that re-
quire a more detailed assessment from a specialist [6].
Various tools are available to screen for cognitive im-
pairment; the most common of which directly assess a
person’s cognition via questions and/or ‘pencil and
paper’ tasks [7]. Such a process provides a ‘snapshot’ of
cognitive function and does not capture cognitive de-
cline; yet, this is a key component of the dementia diag-
nosis. As dementia progresses, insight is often lost and it
can be challenging to obtain evidence of cognitive
changes from the patient themselves. An attractive ap-
proach is to use informants (e.g. formal carers or rela-
tives) with sufficient knowledge of the patient as a
means of identifying any temporal change in cognition
and related function.
There are a number of informant-based interview tools
available that are designed to identify cognitive decline
over time. Recent systematic reviews of the psychometric
properties of commonly employed tools have assessed
the Informant Questionnaire on Cognitive Decline in
the Elderly (IQCODE) [8], the 8-item interview to As-
certain Dementia (AD8) [9] and the General Practitioner
Assessment of Cognition (GPCOG) [10]. The growing
number of dementia screening reviews published across
various sources can be difficult for stakeholders to keep
up with.
This overview of systematic reviews will draw together
information regarding the diagnostic properties of all
reviewed informant-based interview tools. Our primary
intention is to create a summary of the existing evidence
that could help clinicians in selecting an assessment that
could help researchers in planning future test accuracy
studies and that could help policy makers in forming
recommendations around cognitive screening.
Condition of interest and reference standard
The target condition for this diagnostic test accuracy
overview of systematic reviews is all-cause dementia
(clinical diagnosis). Dementia is a syndrome charac-
terised by progressive cognitive or neuropsychological
decline that is sufficient to interfere with usual function-
ing. The clinical diagnosis of dementia is established
through a personal history from the person and/or
suitable collateral sources in combination with direct
examination, via cognitive assessment and supplemen-
tary information from laboratory and radiology
investigations.
The ideal test pathway would involve a person self-
presenting or being referred to a dedicated memory ser-
vice for multidisciplinary assessment that would often
involve clinical examination, repeated cognitive testing
over time and laboratory and imaging testing. While the
approach to diagnosis may vary across differing health-
care systems, comprehensive assessment and demon-
strating functionally important change in cognition over
time is essential. Relatives, friends and caregivers are
well placed to comment on change over time and func-
tional consequences. The diagnostic assessment would,
where possible, include collateral information often in
the form of a detailed interview. The informant screen-
ing tools attempt to capture the most discriminating as-
pects of this interview in a short, standardised
questionnaire.
There are various internationally accepted dementia
diagnostic criteria that help operationalise and standard-
ise the assessment. The most common of which are the
various iterations of the World Health Organization
International Classification of Diseases (ICD) ICD-10
[11] and the American Psychiatric Association Diagnos-
tic and Statistical Manual of Mental Disorders (DSM)
for all-cause dementia and subtypes [12]. The label of
dementia encompasses varying pathologies, and specific
diagnostic criteria are also available for each specific
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dementia subtype, e.g. NINCDS-ADRDA (National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related
Disorders Association) criteria for Alzheimer’s dementia
[13, 14]; McKeith criteria for Lewy Body dementia [15];
Lund criteria for frontotemporal dementias [16]; and the
NINDS-AIREN (National Institute of Neurological Dis-
orders and Stroke Internationale pour la Recherche et
l’Enseignement en Neurosciences) criteria for vascular
dementia [17].
The syndrome of mild cognitive impairment (MCI)
may also be considered in studies looking at cognitive
screening. Varying definitions of MCI have been pro-
posed, usually based on the demonstration of cognitive
deficits beyond what would be expected for age but with
no evidence of functional impairment from these deficits
[18]. MCI is often conceptualised as a precursor to overt
dementia, but progression to dementia from MCI is nei-
ther inevitable nor predictable [19]. While our primary
focus will be dementia, we will also consider studies
looking at test properties of informant tools against an
MCI diagnosis. The suitability of informant question-
naires for the assessment of MCI is uncertain. As the
method adopted by informant questionnaires to estab-
lish cognitive impairment is predominantly via reports
of everyday functional impairment, this might suggest
that they are incompatible with the MCI concept; how-
ever, despite this, a number of studies have sought to
evaluate the value of informant tools to improve MCI
diagnosis in memory clinic settings [20, 21]. Better es-
tablishing the evidence base for use of informant tools to
detect MCI would therefore help to clarify if the use of
informant tools for assessment of non-dementia level
cognitive impairment is appropriate.
Our focus is on informant-based cognitive screening
tests. In practice, these tests would not be used in isola-
tion to a make a clinical diagnosis of dementia. It could
be argued that the target condition being ‘diagnosed’ by
the screening test is a state of possible abnormal cogni-
tion that requires more detailed assessment. To date, the
dementia test accuracy literature has been based on a
more traditional paradigm of comparing the index test
to the final diagnosis of dementia/no dementia [22] and
so we have retained this approach for our review.
Index test
Our index test will be any informant-based interview
tool intended to identify cognitive decline. These typic-
ally consist of questionnaires that are directed to a
spouse, family member or carer. The most commonly
used informant assessments are the IQCODE and the
AD8. Some tests combine informant interviews with dir-
ect to patient assessment, for example the GPCOG.
There are many reasons to favour the use of informant
assessments in dementia screening. Such tools typically
have an immediacy and relevance, which appeals to its
users. In addition, the assessment and scoring process is
usually brief (e.g. < 10 mins) and requires minimal
training. Moreover, there are data to suggest that, by
comparison to standard direct cognitive assessments, in-
formant interviews may be less influenced by cultural
and educational biases [23]. Diagnostic criteria for de-
mentia make explicit reference to documenting decline
as well as the involvement of collateral informants,
emphasising the potential utility of an informant inter-
view tool.
Our index tests are screening tools, rather than diag-
nostic instruments. However, for consistency with other
test accuracy reviews we have retained the descriptor
‘diagnostic test accuracy’ for describing the methods
used in our overview of systematic reviews.
Why an overview of systematic reviews?
A thorough understanding of the diagnostic properties
of informant tools would enable a more informed ap-
proach to testing. Critically evaluating the current
evidence-base regarding the accuracy of informant-based
screening tools is essential to this process. A number of
reviews of the diagnostic properties of informant-based
tools have been produced [24–27]; however, this rapidly
growing body can be overwhelming for clinicians and
decision-makers to fully absorb. Furthermore, these
reviews typically focus upon the properties of informant-
based screening tools in isolation; hence, it is cur-
rently difficult to compare the properties of respective
tools and form valid conclusions as to the suitability
of one tool over another, for instance in a particular
setting. Arguably, a synthesis of reviews is therefore
needed to present a broader picture of the evidence
base, which can then be used to inform the utilisation
of these tools in clinical practice. We will also use
this overview of systematic reviews to ‘map’ the exist-
ing evidence and highlight gaps in the literature for
given tools and specific settings.
The motivation for producing an overview of system-
atic reviews at this time is twofold. Priority setting work
with people living with dementia has emphasised the im-
portance ascribed to the diagnostic approach. To ensure
that diagnosis is as accurate as possible, we felt it would
be useful to collate and compare all the relevant reviews
on a particular approach to assessment [28]. Secondly,
the Cochrane Dementia and Cognitive Improvement
Group have produced a suite of reviews on informant
tests and so we know there is contemporary literature
on which to base an overview of systematic reviews. In-
dividual reviews of test accuracy have been used in re-
cent national guidelines [5]; but a comment from an
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end-user was that having all the evidence in one collec-
tion would be preferable.
Methods
Aims and objectives
Our over-arching aim is to produce an overview of sys-
tematic reviews that offers a synthesis of all systematic
reviews of informant-based cognitive screening tools.
Using the terminology of test accuracy research, our pri-
mary question is: what is the diagnostic accuracy of the
various informant based cognitive screening tools for
making a diagnosis of dementia across various settings
and populations?
Secondary objectives
If data allow, we hope to use the overview of systematic
reviews to inform a number of secondary objectives:
To map the availability and quality of evidence
regarding accuracy of informant-based tests.
To identify gaps in the evidence base where reviews or
primary research are needed.
To summarise accuracy across specific settings
(secondary care, primary care, community) and
populations (neurological disease, delirium, MCI).
To compare informant tests with the intention of
drawing inferences about comparative accuracy.
Design
We used the PRISMA-P (Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols) check-
list for reporting in this overview of systematic reviews
protocol.
We appreciate that the design, conduct and interpret-
ation of an overview of systematic reviews is evolving
[29]. Our approach to the overview of systematic reviews
was informed by the Cochrane Handbook [30] and also
by recent methodological reviews of the overview of sys-
tematic reviews process [31], discussions with authors of
previous and ongoing overviews of systematic reviews
[32] and a UK meeting held by the National Institute of
Health Research Complex Reviews Support Unit (NIHR
CRSU) with a focus on complex review methods. An ini-
tial draft of this protocol was considered by the
Cochrane Test Accuracy Methods Group. The group of-
fered useful comments and suggestions that have been
incorporated into the protocol.
Inclusion and exclusion criteria
We will include any systematic reviews of the literature
meeting our selection criteria. There are no standard,
consensus criteria that define a review as ‘systematic’ for
the purposes of an overview of systematic reviews. For
our overview of systematic reviews, to distinguish a
systematic review (eligible) from a non-systematic litera-
ture review (ineligible), the review must contain a de-
scription of a literature search that used more than one
electronic database, must give explicit inclusion and ex-
clusion criteria, and must offer some attempt at critical
appraisal of the included studies.
Some overviews of systematic reviews have limited
their scope to a specific evidence source, for example
Cochrane reviews. As an intended outcome of our over-
view of systematic reviews is to produce an evidence
‘map’, we considered it important to include all relevant
reviews. We hope that this inclusive approach will allow
for as comprehensive a picture of the current literature
as possible.
In designing an overview of systematic reviews, a priori
decisions need to be made around whether the authors
will update eligible reviews with relevant research pub-
lished after the review. Our overview of systematic re-
views will only include the published systematic review
data. We will not update reviews with additional data
from contemporary studies, and where there is no exist-
ing review, we will not create one for the purposes of
this overview of systematic reviews. We felt this was ap-
propriate as there are a number of recently published re-
views in our topic area and the evidence base around
test accuracy is more ‘stable’ over time than the evidence
base for a novel intervention. We will also avoid correct-
ing imperfections identified in reviews (i.e. lack of risk of
bias assessment for included studies) but rather will note
when these are absent.
To be eligible for inclusion, reviews must meet the fol-
lowing criteria:
1 Performed a systematic search of the published
literature for at least one informant-based cognitive
screening tool.
2 Primarily interested in investigating the diagnostic
properties (test accuracy) of an informant-based
cognitive screening tool(s) and report both sensitiv-
ity and specificity statistics of at least one
informant-based tool.
Thus, our overview of systematic reviews will not in-
clude reviews, editorial or opinion pieces, based on only
a selection of possible literature. There are various ap-
proaches to presenting review data. To be included, the
review should offer, at least, a narrative synthesis with a
focus on the informant test accuracy and/or a quantita-
tive summary of test accuracy data and/or give a struc-
tured assessment of the ‘quality’ of the included studies.
We will make no exclusions on the basis of methodo-
logical quality, use of best practice methods or approach
to data synthesis. Data may allow us to explore these
factors and compare them at the review level. Where
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our search highlights a potentially relevant review that is
only available as an abstract, we will contact the authors
to verify whether a full paper is available.
Describing test setting and populations of special interest
Screening for dementia takes place in various settings
and at different stages in the dementia pathway. In this
overview of systematic reviews, we will only consider re-
views of informant tools that were utilised as part of an
initial assessment for cognitive decline; however, we will
not restrict by setting. We will operationalise the settings
in which informant tools are used as primary care, sec-
ondary care and community.
Primary care shall be defined as settings in which the
patient presents to a non-specialist service, such as gen-
eral practice, because of subjective memory complaints
or because of concerns from others. Patients seen in pri-
mary care are unlikely to have had any previous cogni-
tive assessment. Employment of informant-based
interview tools in these cases can be referred to as ‘tri-
age’ or ‘case-finding’.
Secondary care shall be defined as any settings where
patients are referred for expert input and includes gen-
eral hospitals and more specialist settings such as mem-
ory clinics. Screening in such settings typically involves
opportunistic screening of adults presenting as unsched-
uled admissions, or, in the case of more specialist set-
tings, part of a wider pre-planned assessment, designed
to distinguish those who have dementia from those who
do not. Case-mix in these settings will include patients
with comorbid physical and psychiatric diagnoses, and
prevalence rates of dementia are typically high. Patients
admitted to secondary care are more likely to have had
cognitive assessment prior to referral; albeit this is not
always the case [33]. They may also have had other as-
sessments such as neuroimaging or laboratory tests.
Within the secondary care rubric, we have identified
particular populations of interest, where the informant
based approach may have utility or may have differing
test properties. People living with neurological disorders
such as stroke, multiple sclerosis or Parkinson’s disease
have a high prevalence of cognitive problems but phys-
ical impairments may preclude direct to patient assess-
ment with pencil and paper tests [34]. Patients with the
clinical syndrome of delirium often have pre-existing
cognitive impairment but a direct to patient test will be
confounded by the delirium [35]. In these situations, in-
formant assessment may be particularly useful.
Community settings shall be defined as settings in
which the cohort is unselected, i.e. ‘population screen-
ing’. Prevalence of dementia is likely to be lower in such
settings than that which is found in secondary or pri-
mary care.
Process to identify relevant index tests
We identified tools of interest for our overview of
systematic reviews via a multi-stage process: a group
consultation with experts who had extensive experience
in the use of informant tools for assessing dementia/cog-
nitive impairment, supplemented by scoping the litera-
ture online.
Search methods for identification of reviews
We propose a search strategy with three complementary
approaches. We hope this will ensure that our overview
of systematic reviews is suitably comprehensive.
A) We will perform title searching of all reviews and
protocols in the Cochrane Dementia and Cognitive
Improvement portfolio. We will contact the authors
of any relevant protocols where a complete review
is not published.
B) As part of their ongoing dementia diagnostic test
accuracy work, the Cochrane Dementia and
Cognitive Improvement Group run a sensitive
search across a variety of literature databases. This
regularly updated search is designed to capture all
diagnostic test accuracy studies with a focus on
neuropsychological assessment. We will work with
the latest of these searches looking for any
systematic review titles [36].
C) Using the methods outlined in the earlier section,
we have identified a list of relevant informant
assessments. The assessments of interest are AD8,
Blessed Dementia Scale [37], GPCOG, IQCODE,
Deterioration Cognitive Observee [38], Dementia
Questionnaire [39], Short Memory Questionnaire
[40], Symptoms of Dementia Screener [41] and
Concord Informant Dementia [42]. We will
perform a systematic search for these tests (see
Supplementary materials). The search will use the
test name and any synonyms and combine with a
validated search filter for systematic reviews. The
process will be iterative: if, during the course of the
review, we find an informant-based test that was
not included in our original list, then we will add
this to the list and perform a further systematic
search. This third search will include the following
databases: EMBASE (OVID), Health and Psycho-
social Instruments (OVID), Medline (OVID), CINA
HL (EBSCO), PSYCHinfo (EBSCO) and the PROS-
PERO registry of review protocols. All databases
will be searched from inception to present.
We will contact authors working in the field of de-
mentia test accuracy to identify other relevant systematic
reviews. Should an identified review be in a non-English
language, we will arrange translation. We will contact
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authors of grey literature that is identified by our search
and access theses from institutions known to be involved
in prospective dementia studies. However, we will only
include reviews that have been published in peer
reviewed scientific journals in our final review. We will
study reference lists of all identified reviews in order to
identify additional titles not found by our search and will
repeat this process until no new titles are found [43].
Data collection and analysis
Selection of reviews
Search results will be imported into Covidence software
[44] for deduplication and screening. Two authors (MT
and SN) will independently assess titles and abstracts
identified by our searches and exclude obviously irrele-
vant reviews. The same two authors will then read full
texts of remaining titles and select reviews that meet our
inclusion criteria. In the event of disagreement between
authors, a third, neutral author (JB) shall act as an arbi-
ter if consensus is not reached through discussion. This
process will be illustrated in a PRISMA flow diagram.
Data extraction and management
Two authors (MT and SN) will extract data independ-
ently. Disagreements will be resolved by discussion, with
assistance from a third author (TQ), if necessary. Data
will be extracted on to a data collection proforma that
has been specifically designed by the author team and
piloted on two exemplar reviews—one from Cochrane
[26] and one from non-Cochrane [45]. Specifically, we
will extract and record the details of date of last litera-
ture search; the aims and rationale; primary tools
searched for; included studies; population of interest;
setting (including countries studied in primary papers);
tools evaluated (along with sensitivity and specificity
values of said tools and thresholds evaluated if appropri-
ate); total number included in the review and total num-
ber with dementia; subgroups within the study; and
methods used for assessing ‘quality’ of included studies
(see Supplementary materials).
We anticipate that reviews will use differing ap-
proaches to present their data. Where meta-analytical
data are presented, we will extract the summary mea-
sures but will also record the individual test level data
reported in each review as this will be used to compare
tests via a network meta-analysis. If only a narrative
summary is offered, we will extract the authors’ conclu-
sions on test accuracy. We also recognise that ap-
proaches to the critical appraisal of included studies will
differ between reviews. We will present a summary of
the ‘quality’ of individual studies included in the review
using the approach employed in the primary review.
Assessment of methodological quality of included
reviews
Two authors (MT and SN) will independently assess the
methodological quality of included reviews, basing this
assessment on the AMSTAR-2 (assessment of multiple
systematic reviews) measurement tool [46] and consider-
ing the following key domains.
 Clarity of review objective.
 Description of study eligibility criteria.
 Extent of searching undertaken.
 Transparency of assessment process.
 Assessment of publication bias.
 Assessment of heterogeneity.
The AMSTAR-2 tool offers a series of statements
to guide the assessment. These have been framed in
terms of intervention reviews. Where relevant, we
have modified this guidance to make the materials
appropriate for assessment of test accuracy research.
For example, where the original tool assesses use of
the Patients, Interventions, Control, Outcomes (PICO)
categorisation, our revised tool looks for evidence of
index test, reference standard and setting categorisa-
tion (see Supplementary materials).
We will pilot our revised AMSTAR-2 against two re-
views (one Cochrane [26] and one non-Cochrane [45])
to see if any further study specific modifications are
needed.
We recognise that in primary diagnostic test accuracy
research, assessment of methodological quality is often
complicated by poor reporting. The same may be true of
diagnostic test accuracy reviews. We will complement
our AMSTAR-2 assessment with a specific assessment
of the reporting of included reviews. The same two re-
viewers will evaluate the reporting standard of each re-
view by utilising the PRISMA-DTA (Preferred Reporting
Items for a Systematic Review and Meta-analysis of
Diagnostic Test Accuracy Studies) checklist [47].
When authors on this overview of systematic reviews
are also authors of an included review, they will not be
involved in assessment of methodological or reporting
quality of that review. This will be done independently
by two other authors with access to an independent ar-
bitrator as needed.
Data synthesis
Primary outputs from our overview of systematic reviews
will be tables of included reviews for each informant as-
sessment tool and an evidence ‘map’ describing the sys-
tematic review data available for each tool in each
setting and population of interest. The map will take a
tabulated form, with columns representing each inform-
ant assessment tool and rows representing the settings
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and special populations of interest (secondary care, pri-
mary care, community, neurological disease, delirium
and MCI). Within each resulting cell, we will describe
the systematic review(s) available, the summary measure
of accuracy (if available), the risk of bias of included
studies and the AMSTAR-2 rating for the review. While
we have a plan for illustrating the data, we appreciate
that the data may not be suited to the approach outlined
here. We will explore other methods of visual presenta-
tion of our acquired data.
If data are suitable, we propose quantitative analysis of
test accuracy using MetaDTA version 1 [48]. We will
calculate, where possible, summary estimates of test ac-
curacy for each ‘cell’ of the evidence map. We are princi-
pally interested in the test accuracy of the informant
tools for the dichotomous variable ‘dementia/no demen-
tia’. We will present summary sensitivity, specificity, pre-
dictive values and/or and likelihood ratios. These data
will be combined using the bivariate method [49].
We recognise that the statistical techniques available
for creating aggregate test accuracy data have evolved
since the first test accuracy reviews were published. If
the included review already presents a quantitative ana-
lysis, we will produce our own summary estimates using
the individual study level data contained within the re-
view. If a ‘cell’ has two reviews that contain differing
studies, we will include all relevant studies in our sum-
mary estimate. The quantitative test accuracy summary
analyses will be repeated and restricted to studies at low
risk of bias (based on individual study level data within
the included review).
As a final step, if the data allow, we will attempt indir-
ect comparative analyses using a network-based ap-
proach and ranking the tools based on likely superiority
in terms of sensitivity and specificity [50].
We will then employ a GRADE (Grading of Recom-
mendations Assessment, Development, and Evaluation)
[51] approach to establish overall strength of evidence
for the use of informant tools to screen for dementia,
following recommended guidelines for applying GRADE
to diagnostic tests [52].
Discussion
We anticipate seven potential issues in the selection and
collation of systematic reviews into our overview of sys-
tematic reviews. We outline approaches to these issues
that have been developed in discussion with authors of
existing overview of systematic reviews and with system-
atic review methodologists.
Overlapping reviews: We will not exclude any review
that focuses on the same test as a review already in-
cluded. Similarly, we will not exclude any review that in-
cludes studies that also feature in another included
review. If we identify overlapping reviews, we will
quantify the extent of overlap (noting the reference of
each study included in both reviews). If we find reviews
with the same test and setting/population, we will com-
pare (where available) the review results, describing dif-
ferences in summary accuracy, ‘quality’ assessment, and
conclusions of the review authors. Depending on the na-
ture of the review data, this comparative exercise may be
presented as a table or as narrative text.
Discrepant results: Related to the issue of overlapping
reviews is the situation where two reviews ask the same
question but present seemingly discrepant results. We
will explore potential reasons for this by comparing
search strategies, inclusion/exclusion criteria, critical ap-
praisal methods used within the review and method used
for evidence synthesis.
Forms of bias in individual studies: Informant tool per-
formance may vary based upon particular types of bias,
such as the type of person doing the test or the time lag
duration between index test and reference standard. We
will not explore these possibilities individually in our
overview of systematic reviews, but rather will rely upon
the risk of bias assessments of included reviews. If re-
views do not conduct risk of bias assessments that suffi-
ciently consider such forms of bias, we will highlight this
issue in our overview of systematic reviews.
Historical reviews: Diagnostic test accuracy of an in-
formant questionnaire is unlikely to become outdated or
superseded by a new method. Thus, unlike overviews of
systematic reviews of interventions where historical re-
views may be misleading, we will operate no restrictions
based on the ‘age’ of the review. We will note the dates
of the search. Where a review has been superseded by
an update review, we will include the most contempor-
ary review.
Author’s own reviews: We anticipate that many of the
included reviews will be part of the suite of diagnostic
test accuracy reviews performed by the Cochrane
Dementia and Cognitive Improvement Group. Some of
these reviews will have been authored by authors of this
overview of systematic reviews. We will attempt to en-
sure objectivity and avoid any potential conflicts by pre-
specifying methods in this protocol, by using validated
and operationalised assessment tools and by making sure
that the researchers appraising and extracting data were
not part of the author team on the included review.
Part relevant reviews: There may be systematic reviews
on a broader topic, for example cognitive screening tests
in general, which include informant-based tests. We will
consider reviews where informant assessments are in-
cluded but not the focus of the review if they otherwise
are aligned with inclusion and exclusion criteria. As de-
scribed in our general inclusion/exclusion criteria, for
the review to be eligible it must offer a synthesis of data
specific to the informant tool(s) included.
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Reviews that cover multiple settings/domains: When
constructing our evidence map, we may encounter re-
views that describe evidence over multiple settings, con-
ditions, or populations, and thus do not easily fit into
one particular category. In this circumstance, we will as-
sign a review into each category that is described in that
review. While this may indicate that more reviews are
available than in reality, we will try to mitigate this per-
ception by providing a reference list for each cell so as
to highlight when a single review has been placed in
multiple categories. We will also explore alternate
methods of constructing our evidence map, based upon
the evidence we acquire.
We hope that this overview of systematic reviews will
be of interest to differing groups. Previous overviews of
systematic reviews of diagnostic test accuracy for de-
mentia exist [53], but they focus solely on the methodo-
logical quality of available reviews and do not provide a
concise summary of reported test accuracy. These older
diagnostic test accuracy overviews of systematic reviews
describe the quality of systematic reviews as being sub-
optimal. Our overview of systematic reviews will provide
an update that will determine if the standard is
improving.
In addition, the clinical content described in our over-
view of systematic reviews should be useful to clinicians
and policy makers as it allows a synthesis of the accuracy
of various test approaches. The evidence map, in par-
ticular the evidence gaps, will be of interest to re-
searchers and funders as it may highlight areas to
prioritise future test accuracy research. The process and
approaches used to create the overview of systematic re-
views will be of interest to the evidence synthesis com-
munity. Overview of systematic reviews of test accuracy
is a novel area, with no consensus on the best approach.
This overview of systematic reviews will serve as an ex-
ample of a particular method that could be applied to
other topic areas.
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